
Keywords: تداوم آنتی بادی; Rheumatoid arthritis; Immunosuppressive therapy; 13-valent pneumococcal conjugate vaccine; Immunogenicity; Antibody persistence; RA; Rheumatoid arthritis patients; HC; Healthy control subjects; PnPS; pneumococcal polysaccharides; PCV13; 13-valent pneumoco